Home LiteratureArticle Details
PMID: 18355813 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects.

Gastroenterology ·Vol. 134 ·No. 5 ·2008-05-00 ·Pages 1369-75

Korenblat KM, Fabbrini E, Mohammed BS, Klein S

Abstract

Nonalcoholic fatty liver disease is associated with insulin resistance and diabetes. The purpose of this study was to determine the relationship between intrahepatic triglyceride (IHTG) content and insulin action in liver (suppression of glucose production), skeletal muscle (stimulation of glucose uptake), and adipose tissue (suppression of lipolysis) in nondiabetic obese subjects. A euglycemic-hyperinsulinemic clamp procedure and stable isotopically labeled tracer infusions were used to assess insulin action, and magnetic resonance spectroscopy was used to determine IHTG content, in 42 nondiabetic obese subjects (body mass index, 36 +/- 4 kg/m(2)) who had a wide range of IHTG content (1%-46%). Hepatic insulin sensitivity, assessed as a function of glucose production rate and plasma insulin concentration, was inversely correlated with IHTG content (r = -0.599; P < .001). The ability of insulin to suppress fatty acid release from adipose tissue and to stimulate glucose uptake by skeletal muscle were also inversely correlated with IHTG content (adipose tissue: r = -0.590, P < .001; skeletal muscle: r = -0.656, P < .001). Multivariate linear regression analyses found that IHTG content was the best predictor of insulin action in liver, skeletal muscle, and adipose tissue, independent of body mass index and percent body fat, and accounted for 34%, 42%, and 44% of the variability in these tissues, respectively (P < .001 for each model). These results show that progressive increases in IHTG content are associated with progressive impairment of insulin action in liver, skeletal muscle, and adipose tissue in nondiabetic obese subjects. Therefore, nonalcoholic fatty liver disease should be considered part of a multiorgan system derangement in insulin sensitivity.

MeSH Terms
Absorptiometry, Photon Adipose Tissue/metabolism Adult Biomarkers/metabolism Body Mass Index Energy Metabolism Female Glucose Clamp Technique Humans Insulin/metabolism Insulin Resistance/physiology Liver/metabolism Magnetic Resonance Imaging Magnetic Resonance Spectroscopy Male Muscle, Skeletal/metabolism Obesity/diagnosis,metabolism Prognosis Risk Factors Triglycerides/metabolism
Chemicals
Biomarkers Insulin Triglycerides
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Korenblat Kevin M
Center for Human Nutrition, Washington University School of Medicine, St Louis, Missouri, USA.
Fabbrini Elisa
Mohammed B Selma
Klein Samuel
References (39)
39 references, click to expand
  1. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.
    Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E462-8 PMID: 15339742
  2. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome.
    Hepatology. 2002 Feb;35(2):373-9 PMID: 11826411
  3. Improved accuracy and precision of gas chromatography/mass spectrometry measurements for metabolic tracers.
    Metabolism. 1998 Jun;47(6):706-12 PMID: 9627371
  4. Nonalcoholic fatty liver disease.
    N Engl J Med. 2002 Apr 18;346(16):1221-31 PMID: 11961152
  5. What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean?
    Diabetes. 2003 Jul;52(7):1641-8 PMID: 12829627
  6. Relationship of hepatic steatosis to adipose tissue distribution in pediatric nonalcoholic fatty liver disease.
    J Pediatr Gastroenterol Nutr. 2006 Jan;42(1):83-8 PMID: 16385259
  7. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis.
    Ann Hepatol. 2006 Jan-Mar;5(1):30-3 PMID: 16531962
  8. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans.
    Diabetes Care. 2006 Apr;29(4):853-7 PMID: 16567827
  9. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance.
    Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E906-16 PMID: 12959938
  10. Assessment of intrahepatic triglyceride content using magnetic resonance spectroscopy.
    J Cardiometab Syndr. 2007 Spring;2(2):136-8 PMID: 17684473
  11. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.
    Nat Med. 2005 Feb;11(2):183-90 PMID: 15685173
  12. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.
    J Clin Invest. 1989 Jul;84(1):205-13 PMID: 2661589
  13. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
    Gastroenterology. 2001 Apr;120(5):1183-92 PMID: 11266382
  14. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
    Hepatology. 2005 Jun;41(6):1313-21 PMID: 15915461
  15. Whole body and abdominal lipolytic sensitivity to epinephrine is suppressed in upper body obese women.
    Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E1144-52 PMID: 10827018
  16. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients.
    Lipids. 2001 Oct;36(10):1117-24 PMID: 11768156
  17. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus.
    J Clin Endocrinol Metab. 1991 Jan;72(1):96-107 PMID: 1986032
  18. The Michigan alcoholism screening test: the quest for a new diagnostic instrument.
    Am J Psychiatry. 1971 Jun;127(12):1653-8 PMID: 5565851
  19. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men.
    Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18273-7 PMID: 17114290
  20. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.
    Diabetes. 2001 Aug;50(8):1844-50 PMID: 11473047
  21. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.
    J Clin Endocrinol Metab. 2002 Jul;87(7):3023-8 PMID: 12107194
  22. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk.
    Diabetologia. 2004 Aug;47(8):1360-9 PMID: 15309287
  23. Assessment of insulin sensitivity in vivo.
    Endocr Rev. 1985 Winter;6(1):45-86 PMID: 3884329
  24. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
    Hepatology. 2003 Oct;38(4):1008-17 PMID: 14512888
  25. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study.
    Diabetologia. 2004 Jan;47(1):31-9 PMID: 14666364
  26. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome.
    Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12587-94 PMID: 17640906
  27. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States.
    Hepatology. 2006 May;43(5):1145-51 PMID: 16628637
  28. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.
    Diabetes Care. 1999 Sep;22(9):1462-70 PMID: 10480510
  29. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease.
    Hepatology. 2005 Aug;42(2):473-80 PMID: 15981216
  30. Heated hand vein blood is satisfactory for measurements during free fatty acid kinetic studies.
    Metabolism. 1991 Apr;40(4):406-9 PMID: 2011082
  31. Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment.
    J Lipid Res. 1999 Nov;40(11):2118-24 PMID: 10553015
  32. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.
    Gastroenterology. 2003 Jan;124(1):71-9 PMID: 12512031
  33. The natural history of nonalcoholic fatty liver disease: a population-based cohort study.
    Gastroenterology. 2005 Jul;129(1):113-21 PMID: 16012941
  34. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.
    Gastroenterology. 2007 Aug;133(2):496-506 PMID: 17681171
  35. Disordered lipid metabolism and the pathogenesis of insulin resistance.
    Physiol Rev. 2007 Apr;87(2):507-20 PMID: 17429039
  36. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.
    Diabetologia. 2005 Apr;48(4):634-42 PMID: 15747110
  37. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.
    Hepatology. 2003 Apr;37(4):917-23 PMID: 12668987
  38. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.
    Hepatology. 2002 Feb;35(2):367-72 PMID: 11826410
  39. Overproduction of large VLDL particles is driven by increased liver fat content in man.
    Diabetologia. 2006 Apr;49(4):755-65 PMID: 16463046
Article Info
Journal
Gastroenterology
Abbr.
Gastroenterology
ISSN
1528-0012
Published
2008-05-00
Epub
2008-00-30
Pages
1369-75
Language
English
Region
United States
NLM ID
0374630
PMCID
PMC2629391
Subset
IM
Grants
NCRR NIH HHS · M01 RR000036-47 · United States
NIDDK NIH HHS · DK 37948 · United States
NCRR NIH HHS · M01 RR000036 · United States
NIDDK NIH HHS · R01 DK037948-22 · United States
NIGMS NIH HHS · P41 GM103422 · United States
NIDDK NIH HHS · P30 DK056341 · United States
NIDDK NIH HHS · P30 DK056341-07 · United States
NCRR NIH HHS · P41 RR000954-31 · United States
NCRR NIH HHS · RR-00954 · United States
NIDDK NIH HHS · R01 DK037948 · United States
NCRR NIH HHS · RR-00036 · United States
NIDDK NIH HHS · DK 56341 · United States
NCRR NIH HHS · P41 RR000954 · United States
NIDDK NIH HHS · P30 DK052574 · United States
NIDDK NIH HHS · DK 52574 · United States
NIDDK NIH HHS · P30 DK052574-10 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]